# IBTK

## Overview
The IBTK gene encodes the inhibitor of Bruton tyrosine kinase (IBTK), a protein that plays a crucial role in the regulation of immune responses and cellular homeostasis. As a substrate receptor for the Cullin 3-dependent E3 ubiquitin ligase complex, IBTK is involved in the ubiquitination and degradation of specific proteins, thereby influencing protein synthesis and turnover (Albano2018The; Vecchio2019IBTK). The protein is primarily localized in the cytoplasm, where it interacts with Bruton’s tyrosine kinase (BTK) to modulate B-cell receptor signaling, impacting B-cell differentiation and survival (Albano2018The). Additionally, IBTK is implicated in cellular stress responses and oncogenic translation processes, highlighting its significance in both normal immune function and pathological conditions such as hematological malignancies (Jiao2024mTORC1S6K1; Albano2018The).

## Function
The IBTK gene encodes a protein that functions as an inhibitor of Bruton's tyrosine kinase (BTK), a key enzyme in B-cell receptor signaling. In healthy human cells, the IBTK protein is involved in several molecular processes, including the regulation of protein turnover and RNA metabolism. It acts as a substrate receptor for the Cullin 3-dependent E3 ubiquitin ligase complex, promoting the ubiquitination and proteasomal degradation of Pdcd4, a translational inhibitor. This activity enhances both cap-dependent and independent translation, influencing protein synthesis and turnover (Albano2018The; Vecchio2019IBTK).

IBTK is primarily active in the cytoplasm, where it interacts with BTK to modulate immune responses and maintain cellular homeostasis. By inhibiting BTK, IBTK plays a role in regulating B-cell differentiation and survival, which is crucial for proper immune function (Albano2018The). The protein's activity is also linked to cellular stress responses, as its expression increases in response to stressors like titanium dioxide and endoplasmic reticulum stress inducers, which is necessary for cell survival (Albano2018The). These functions suggest that IBTK is integral to maintaining cellular balance and supporting immune cell function.

## Clinical Significance
The IBTK gene is clinically significant due to its role in various hematological malignancies, particularly chronic lymphocytic leukemia (CLL) and B-cell lymphomas. In CLL, IBTK expression is progressively upregulated, contributing to resistance to apoptosis and disease progression. This upregulation is associated with the down-regulation of pro-apoptotic genes, such as TNF, CRADD, CASP7, BNIP3, and BIRC3, which promotes the survival and proliferation of CLL cells (Albano2018The). The increased expression of IBTKα, a transcript of the IBTK gene, is linked to the aggressiveness of the disease and is considered a potential marker for treatment effectiveness, as its levels decrease in patients undergoing therapy (Albano2018The).

In the context of Myc-driven B-cell lymphomas, IBTK plays a role in the tumor microenvironment. Haploinsufficiency of IBTK leads to increased tumor angiogenesis and altered immunophenotype, characterized by enhanced recruitment of tumor-associated macrophages and elevated levels of pro-angiogenic factors like VEGF and MMP-9 (Vecchio2020IBTK). The loss of IBTK in Eμ-myc transgenic mice results in increased apoptosis and delayed tumor onset, indicating its pro-survival role in B-cell lymphomagenesis (Vecchio2019IBTK). These findings suggest that IBTK is a potential target for therapeutic interventions aimed at sensitizing tumor cells to apoptosis.

## Interactions
IBTK, the inhibitor of Bruton tyrosine kinase, is involved in several protein interactions that influence cellular signaling pathways. It directly interacts with Bruton’s tyrosine kinase (Btk), binding efficiently to the full-length Btk and specific regions such as the PH domain and the unique Btk motif (BM). This interaction inhibits Btk's kinase activity, affecting downstream processes like calcium mobilization and NF-κB-driven transcription in B cells (Liu2001Direct).

IBTK also interacts with components of the eIF4A family, including eIF4A1, eIF4A2, and eIF4A3. It is involved in the assembly of a CRL3 ubiquitin ligase complex, mediating non-degradative ubiquitination of eIF4A1 and eIF4A2, which promotes cap-dependent translation initiation and oncogenic translation (Jiao2024mTORC1S6K1). The phosphorylation of IBTK by mTORC1 and S6K1 enhances its ability to mediate these interactions, playing a role in sustaining oncogenic translation (Jiao2024mTORC1S6K1).

IBTK's interaction with Btk and eIF4A family proteins highlights its role in regulating both immune responses and translation processes, with implications in cancer cell malignancy and B-cell function.


## References


[1. (Jiao2024mTORC1S6K1) Dongyue Jiao, Huiru Sun, Xiaying Zhao, Yingji Chen, Zeheng Lv, Qing Shi, Yao Li, Chenji Wang, and Kun Gao. Mtorc1/s6k1 signaling promotes sustained oncogenic translation through modulating crl3ibtk-mediated ubiquitination of eif4a1 in cancer cells. eLife, May 2024. URL: http://dx.doi.org/10.7554/elife.92236, doi:10.7554/elife.92236. This article has 0 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.7554/elife.92236)

[2. (Liu2001Direct) Weimin Liu, Ileana Quinto, Xueni Chen, Camillo Palmieri, Ronald L. Rabin, Owen M. Schwartz, David L Nelson, and Giuseppe Scala. Direct inhibition of bruton’s tyrosine kinase by ibtk, a btk-binding protein. Nature Immunology, 2(10):939–946, October 2001. URL: http://dx.doi.org/10.1038/ni1001-939, doi:10.1038/ni1001-939. This article has 65 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/ni1001-939)

[3. (Albano2018The) Francesco Albano, Federico Chiurazzi, Selena Mimmi, Eleonora Vecchio, Arianna Pastore, Clementina Cimmino, Camilla Frieri, Enrico Iaccino, Antonio Pisano, Gaetanina Golino, Giuseppe Fiume, Massimo Mallardo, Giuseppe Scala, and Ileana Quinto. The expression of inhibitor of bruton’s tyrosine kinase gene is progressively up regulated in the clinical course of chronic lymphocytic leukaemia conferring resistance to apoptosis. Cell Death &amp; Disease, January 2018. URL: http://dx.doi.org/10.1038/s41419-017-0026-3, doi:10.1038/s41419-017-0026-3. This article has 22 citations.](https://doi.org/10.1038/s41419-017-0026-3)

[4. (Vecchio2020IBTK) Eleonora Vecchio, Giuseppe Fiume, Chiara Mignogna, Enrico Iaccino, Selena Mimmi, Domenico Maisano, Francesco Trapasso, and Ileana Quinto. Ibtk haploinsufficiency affects the tumor microenvironment of myc-driven lymphoma in e-myc mice. International Journal of Molecular Sciences, 21(3):885, January 2020. URL: http://dx.doi.org/10.3390/ijms21030885, doi:10.3390/ijms21030885. This article has 6 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms21030885)

[5. (Vecchio2019IBTK) Eleonora Vecchio, Gaetanina Golino, Antonio Pisano, Francesco Albano, Cristina Falcone, Simona Ceglia, Enrico Iaccino, Selena Mimmi, Giuseppe Fiume, Giorgio Giurato, Domenico Britti, Giuseppe Scala, and Ileana Quinto. Ibtk contributes to b-cell lymphomagenesis in eμ-myc transgenic mice conferring resistance to apoptosis. Cell Death &amp; Disease, April 2019. URL: http://dx.doi.org/10.1038/s41419-019-1557-6, doi:10.1038/s41419-019-1557-6. This article has 19 citations.](https://doi.org/10.1038/s41419-019-1557-6)